Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update
2016 Genitourinary Cancers Symposium
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
Maha Hussain, MD
Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
Hans-Joerg Hammers, MD, PhD
Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 monotherapy and future PD-1 combination therapies for renal cell carcinoma.
Paul L. Nguyen, MD
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
Fred Saad, MD
Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.
Srikala S. Sridhar, MD
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.